

Date: May 21, 2020

1. The Manager- Listing

National Stock Exchange of India Limited

(Scrip Code: NAUKRI)

2. The Manager- Listing BSE Limited

(Scrip Code: 532777)

Dear Sir/Madam,

Sub: <u>Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements)</u>
Regulations, 2015

The Company would like to inform you that IE Venture Fund I has entered into an agreement to invest about Rs.3.70 Crore in Intellihealth Solutions Private Limited. The details of the transaction are given as under:

Sl.	Particulars	Details		
No. 1.	Name of the target entity, details in brief such as size, turnover etc.	Intellihealth Solutions Private Limited ("Truemeds")		
		No. 306, A-WING, 3rd Floor,Pranik Chamber Owners Co.op Prem Society Ltd, Saki Vihar Road, Sakinaka Mumbai -400072		
		Turnover (As on 31.03.2020): Rs. 1 Crore (Unaudited Figure)		
2.	Whether the acquisition would fall within related party transaction(s) and whether the	Truemeds is not a Related Party as on the date of making this Investment. Promoters of the Company have no interest in the said investment. The transaction is done at Arm's Length basis. Truemeds is a Tele-health platform focused on selling top company Traded Generics/substitute medicines to consumers. Its telemedicine platform of doctors advises consumers about substitute medicines (offered by top pharma companies but at much cheaper costs) which could significantly reduce cost of their medical bills.		
	promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"			
3.	Industry to which the entity being acquired belongs			
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity.	The said investment would help IE Venture Fund I to support and grow Truemeds business in India.		
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.		

(W)



6.	Indicative time period for completion of acquisition	Immediate		
7.	Nature of Consideration whether cash	Cash Consideration		
/.		Cash Consideration		
	consideration or share swap and details of the same.	11 . D 0.50 G		
8.	Cost of acquisition or the price at which the shares	About Rs. 3.70 Crore		
	are acquired.	May rights		
9.	Percentage of shareholding/control acquired and/ or	The IE Venture Fund I has agreed to acquire		
	number of shares acquired.	24,980 -0.01% Series Seed Compulsorily		
		Convertible Preference Shares having Face		
	,	value of Rs.10/- each at a premium of		
	,	Rs.1,468.79/ The aggregate shareholding of IE		
		Venture Fund I, post this investment, in		
		Truemeds would be 17.80% on a fully		
		converted & diluted basis.		
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Truemeds which was incorporated on February 1, 2019 is a Tele-health platform focused on selling top company Traded Generics/substitute medicines to consumers. Its telemedicine platform of doctors advises consumers about substitute medicines (offered by top pharma companies but at much cheaper costs) which could significantly reduce cost of their medical bills.		
		Last three years turnover:		
		2019-2020	2018-19	2017-2018
		Rs. 1 Crore		
		(Unaudited	NA	NA
	е	figure)		1

This is for your information and records.

Thanking You.

Yours faithfully,

For Info Edge (India) Ltd.

MM Jain

SVP- Secretarial & Company Secretary

Regd. Office: Ground Floor, 12A, 94, Meghdoot, Nehru Place, New Delhi-110019